Carl Zeiss Meditec AG (AFX)
XETRA Stock Exchange · Germany · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 35.10 |
|---|---|
| 52-week range | 22.62 – 48.20 |
| Return, 1 month / 3 months | +18.9% / +24.5% |
| Return, 1 year / 3 years | −24.2% / −52.1% |
| Trend | Uptrend |
| RSI (14) | 72 |
| Volatility (1 year) | 44.5% |
| Worst drawdown (1 year) | -49.2% |
| Average daily value traded | 6.64M EUR |
| Dividend yield | 1.6% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Carl Zeiss Meditec makes medical devices for eye care and microsurgery. Its products include diagnostic instruments for examining the eye, laser systems and equipment used in cataract and refractive surgery, surgical microscopes, and intraocular lenses implanted during eye operations. Hospitals, eye clinics and specialist physicians are its main customers, and the company is based in Jena, Germany, with operations in many countries.
The shares are listed on the XETRA Stock Exchange in Germany under the code AFX, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Carl Zeiss Meditec AG (AFX) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 35.10 on 22 October 2026.
Its price-based Market X-Ray is 58 out of 100 (a fair price profile), ranking 281 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 24.2% and over the last three months it rose 24.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 73 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 24.0% | ||
| From 52-week high | -25.9% | ||
| Momentum | 64 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 24.5% | ||
| 6-month return | 26.5% | ||
| 12-month return, skipping the last month | -36.3% | ||
| Stability (higher is calmer) | 26 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 44.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -49.2% | ||
| Liquidity | 88 · Strong | Trades actively. | |
| Average daily value traded | 6.64M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 40 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.6% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | +7.2% |
|---|---|
| 1 month | +18.9% |
| 3 months | +24.5% |
| 6 months | +26.5% |
| 1 year | −24.2% |
| 3 years | −52.1% |
| 5 years | −78.2% |
Signals
| 50-day / 200-day average | 31.65 / 28.30 |
|---|---|
| Golden / death cross (60 days) | Golden, 35 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.04 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 27 Mar 2026 | EUR 0.5500 |
| 27 Mar 2025 | EUR 0.6000 |
| 22 Mar 2024 | EUR 1.1000 |
| 23 Mar 2023 | EUR 1.1000 |
| 31 Mar 2022 | EUR 0.9000 |
| 28 May 2021 | EUR 0.5000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.